Komori
Changes in Officers4534Mochida Pharmaceutical Co.,Ltd.Pharmaceuticals

Notice of personnel changes

Effective 25 June 2026, 3 executive officers will be newly appointed and 1 will retire. The responsibilities of several executive officers will also change, and the Legal Affairs & Compliance Department will be divided into the Legal Affairs Department and the Corporate Ethics Promotion Department.

Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Who is moving to which position

Incoming appointee

3 items
Scheduled Appointment DateEffective 25 June 2026
Kitamura Keiko (北村 圭子)
Previous positionGeneral Manager of the Biomaterials Business Division
New positionExecutive Officer, in charge of the Biomaterials Business, concurrently serving as General Manager of the Biomaterials Business Division
Ishikura Hiroaki (石倉 宏明)
Previous positionDeputy General Manager of the Pharmaceutical Development Division, in charge of pharmaceutical development
New positionExecutive Officer, General Manager of the Pharmaceutical Development Division
Ito Hiroshi (伊藤 浩)
Previous positionDeputy General Manager of the Pharmaceutical Sales Division, in charge of branches
New positionDeputy General Manager of the Pharmaceutical Sales Division, in charge of branches

Departing officer

1 item
Date of departureEffective 25 June 2026
Mizuno Hitoshi (水野 均)Next role stated
Former PositionSenior Executive Officer, in charge of the Biomaterials Business
New positionRetirement

“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.

Whether the incumbent will remain in office (whether they will retain their position)

Whether he will remain on the Board of Directors: Not disclosed

Details of organizational changes

The Legal Affairs & Compliance Department of the Corporate Planning and Administration Division will be divided into the Legal Affairs Department and the Corporate Ethics Promotion Department, and the Legal Affairs Department will be transferred to the direct supervision of the officer in charge of legal affairs.

Who is moving to which position
ItemDetails
Scheduled Appointment DateEffective 25 June 2026
Date of departureEffective 25 June 2026
Name of appointeeKitamura Keiko (北村 圭子), Ishikura Hiroaki (石倉 宏明), Ito Hiroshi (伊藤 浩)
Appointee's new positionExecutive Officer, in charge of the Biomaterials Business, concurrently serving as General Manager of the Biomaterials Business Division, Executive Officer, General Manager of the Pharmaceutical Development Division, Deputy General Manager of the Pharmaceutical Sales Division, in charge of branches
Appointee's previous positionGeneral Manager of the Biomaterials Business Division, Deputy General Manager of the Pharmaceutical Development Division, in charge of pharmaceutical development, Deputy General Manager of the Pharmaceutical Sales Division, in charge of branches
Name of departing officerMizuno Hitoshi (水野 均)
Former position of departing officerSenior Executive Officer, in charge of the Biomaterials Business
New position of departing officerRetirement
Whether the incumbent will remain in officeWhether he will remain on the Board of Directors: Not disclosed
Details of organizational changesThe Legal Affairs & Compliance Department of the Corporate Planning and Administration Division will be divided into the Legal Affairs Department and the Corporate Ethics Promotion Department, and the Legal Affairs Department will be transferred to the direct supervision of the officer in charge of legal affairs.
Items this document does not state (10)
Resolution dateAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeReason for departureReason for changeReasons for appointmentNumber of directors after the changeChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company stated that the division of the Legal Affairs & Compliance Department and the transfer of the Legal Affairs Department to the direct supervision of the officer in charge of legal affairs are intended to strengthen functions and improve operational efficiency. No individual reasons were provided for the personnel changes involving the executive officers.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of personnel changes | Mochida Pharmaceutical Co.,Ltd. (4534) timely disclosure | Komori